FIG
10 Dec 2020
Trial Summary
The aim of this study is to evaluate the the PET imaging agent, O-(2-[18F]-fluoroethyl)L-tyrosine (FET) to definitively establish the role of FET-PET in the management of brain cancer (Glioblastoma).
Acronym:
FIG
ACTRN/NCT /ethics:
ACTRN12619001735145
Scientific title:
Prospective, multicentre trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography in Glioblastoma (FET-PET in Glioblastoma)
Sponsor / Cooperative group:
Trans Tasman Radiation Oncology Group (TROG)
Trial & Patient Characteristics
| Cancer Type | Brain & central nervous system |
|---|---|
| Trial Type | Treatment |
| Phase | All phases |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Glioblastoma |
| Cancer Stage | All stages |
| Anticipated Start Date | 2020-02-03 |
| Anticipated End Date | 2023-05-01 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Associate Professor Peter Gorayski |
| Recruitment Status | Recruiting |